№ lp_1_2_51806
File format: docx
Character count: 44425
File size: 83 KB
Chimeric antigen receptor (CAR-) T cell therapy is explored as a promising treatment for multiple myeloma, addressing affordability and access challenges in this position paper from clinical and healthcare experts in the European Society for Blood and Marrow Transplantation.
Year:
2022
Region / city:
Europe
Topic:
Hematology, Multiple Myeloma, CAR-T Cell Therapy
Document Type:
Position Paper
Organization:
European Society for Blood and Marrow Transplantation (EBMT)
Author:
Nico Gagelmann, Anna Sureda, Silvia Montoto, John Murray, Natacha Bolaños, Michelle Kenyon, Meral Beksac, Stefan Schönland, Patrick Hayden, Hans Scheurer, Kate Morgan, Laurent Garderet, Donal P. McLornan, Annalisa Ruggeri
Target Audience:
Clinicians, Researchers, Healthcare Providers
Period of Action:
Ongoing
Approval Date:
Not specified
Date of Changes:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
Not specified
Region / City:
Not specified
Topic:
Haematopoietic Stem Cell Transplantation Nursing
Document Type:
Terms of Reference
Organization:
European Society for Blood and Marrow Transplantation (EBMT)
Author:
Not specified
Target Audience:
Nurses and healthcare professionals involved in HSCT
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2026
Region / City:
European Union
Subject:
Patient consent, Data privacy, Blood and marrow transplantation
Document Type:
Consent Form
Organization / Institution:
European Society for Blood and Marrow Transplantation (EBMT)
Author:
EBMT
Target Audience:
Patients, Guardians, Healthcare Providers
Validity Period:
Indefinite
Approval Date:
2026
Amendment Date:
N/A
Year:
2025
Region / city:
Philadelphia, PA
Theme:
Cell and gene therapy, CAR-T cell therapy, cancer treatment
Document type:
Symposium agenda
Author:
Various speakers from Penn Medicine and affiliated institutions
Target audience:
Hematologist-oncologists, medical oncologists, immunologists, researchers, healthcare professionals, patients and caregivers
Period of validity:
April 30, 2025 - May 2, 2025
Approval date:
Not specified
Date of changes:
Not specified
Year:
2024
Region / city:
N/A
Topic:
Clinical trials, CAR-T therapy, cancer treatment
Document type:
Research study
Organization / institution:
N/A
Author:
Neelapu et al., Schuster et al., Abramson et al., Jacobson et al., Fowler et al., Morschhauser et al., Wang et al.
Target audience:
Oncology professionals, researchers, healthcare providers
Period of validity:
N/A
Approval date:
N/A
Date of changes:
N/A
Year:
2023
Region / City:
Asia
Topic:
Cancer Research, Cell Therapy, Immunotherapy
Document Type:
Review Article
Institution:
Asian Oncology Research Journal
Author:
Sepideh KarkonShayan
Target Audience:
Scientific Community, Oncologists, Immunologists
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Section:
Supplemental Methods
Field:
Immunology and Hematologic Malignancies
Experimental focus:
B7-H3 CAR-T cells in acute myeloid leukemia (AML)
Monoclonal antibodies:
Anti-human CD markers and related reagents for flow cytometry
Suppliers:
Becton-Dickinson (BD) Biosciences; Miltenyi Biotec; BioLegend; Jackson ImmunoResearch Labs
Cell lines:
THP1; U937; HL-60; Kasumi-1; OCI-AML2; OCI-AML3
Primary samples:
DFAM-6855; CBAM-44728 from Public Repository of Xenografts (PRoXe), Dana-Farber Cancer Institute
Biological material:
Primary AML blasts; donor PBMCs; buffy coats from healthy volunteers
Vector system:
SFG retroviral vector with MoMLV gag-pol and RD114 envelope
Transduction method:
Retronectin-coated plates with retroviral supernatant
Cell expansion cytokines:
IL7; IL15
Statistical methods:
Mann Whitney test; one-way ANOVA with Holm-Sidak adjustment; Chi-square test
Software:
Prism version 8 (GraphPad)
Sample origin:
Bone marrow and peripheral blood from AML patients
Animal model:
NSG mice for in vivo expansion of xenografts
Culture conditions:
RPMI-1640 medium with fetal bovine serum, L-glutamine, penicillin, and streptomycin
Year:
2023
Event Date:
September 23, 2023
Region / City:
Halifax, Nova Scotia, Canada
Type:
Fundraising Campaign
Organization:
QEII Health Sciences Centre
Cause:
Cancer Research and Treatment
Target Audience:
Potential Donors and Supporters
Therapy Focus:
CAR-T Cell Therapy for Blood Cancer
Objective:
Establishment of CAR-T Therapy Lab and Funding Cancer Care Initiatives
Year:
2024
Region / city:
United Kingdom
Topic:
Health technology assessment
Document type:
Appeal hearing report
Organization:
National Institute for Health and Care Excellence (NICE)
Author:
NICE
Target audience:
Healthcare professionals, industry representatives, public
Period of validity:
Not specified
Approval date:
23 September 2024
Date of changes:
Not specified
Year:
2023
Region / City:
Manchester, London
Topic:
Health Services Research, Myeloma Treatment
Document Type:
Research Grant Announcement
Organization / Institution:
Myeloma UK
Author:
Sarah Richard, Prof Sarah Garner, Dr Alberto Rocci
Target Audience:
Researchers, Healthcare Professionals, Myeloma Patients
Period of Action:
2023–2025
Approval Date:
2023
Modification Date:
N/A
Year:
2017
Region / City:
Texas
Subject:
Healthcare, Cancer Treatment
Document Type:
Report
Organization / Institution:
MD Anderson Cancer Center
Author:
Not specified
Target Audience:
Healthcare professionals, administrators
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2016
Region / city:
Australia
Topic:
Multiple myeloma treatment
Document type:
Submission for listing consideration
Organ / institution:
PBAC (Pharmaceutical Benefits Advisory Committee)
Author:
Takeda Pharmaceuticals Australia Pty Ltd
Target audience:
PBAC, healthcare professionals
Period of validity:
Ongoing treatment
Approval date:
15 November 2016
Date of changes:
N/A
Year:
2026
Region:
Laboratory mouse model, C57BL6/KaLwRij
Subject:
Multiple myeloma, osteoblast biology, Runx2 gene function
Document type:
Research supplementary methods
Institution:
Academic research laboratory
Authors:
Not specified
Target audience:
Biomedical researchers, immunologists, oncologists
Experimental period:
Mouse model development and analysis up to 3 months of age
Methods:
Bioluminescence imaging, ELISA, cytokine array, osteoblast isolation and culture, ALP staining, Western blot, cell migration assays, flow cytometry
Genes studied:
Runx2, Samsn1
Cell types:
Osteoblasts, 5TGM1 multiple myeloma cells